These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6171523)

  • 1. Increased vasoactive mediator releasability: a possible pathogenic factor of atopic dermatitis.
    Ring J
    Int Arch Allergy Appl Immunol; 1981; 66 Suppl 1():156-8. PubMed ID: 6171523
    [No Abstract]   [Full Text] [Related]  

  • 2. Basophil histamine release and leukotriene production in response to anti-IgE and anti-IgE receptor antibodies. Comparison of normal subjects and patients with urticaria, atopic dermatitis or bronchial asthma.
    Bischoff SC; Zwahlen R; Stucki M; Müllner G; de Weck AL; Stadler BM; Dahinden CA
    Int Arch Allergy Immunol; 1996 Jul; 110(3):261-71. PubMed ID: 8688673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control mechanisms of human basophil releasability.
    Marone G; Poto S; Giugliano R; Celestino D; Bonini S
    J Allergy Clin Immunol; 1986 Nov; 78(5 Pt 2):974-80. PubMed ID: 2431024
    [No Abstract]   [Full Text] [Related]  

  • 4. Altered releasability of vasoactive mediator secreting cells in atopic eczema.
    Ring J; Dorsch W
    Acta Derm Venereol Suppl (Stockh); 1985; 114():9-23. PubMed ID: 2408433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous histamine levels and histamine releasability from the skin in atopic dermatitis and hyper-IgE-syndrome.
    Ruzicka T; Glück S
    Arch Dermatol Res; 1983; 275(1):41-4. PubMed ID: 6189456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human basophil releasability. II. Changes in basophil releasability in patients with atopic dermatitis.
    Marone G; Giugliano R; Lembo G; Ayala F
    J Invest Dermatol; 1986 Jul; 87(1):19-23. PubMed ID: 2425005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canine leucocyte histamine release: response to antigen and to anti-IgE.
    Jackson HA; Miller HR; Halliwell RE
    Vet Immunol Immunopathol; 1996 Oct; 53(3-4):195-206. PubMed ID: 8969041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro histamine and serotonin release studies in atopic dermatitis.
    Ring J; O'Connor R
    Int Arch Allergy Appl Immunol; 1979; 58(3):322-30. PubMed ID: 84801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of S-lactoylglutathione and inhibitors of glyoxalase I on histamine release from human leukocytes.
    Gillespie E
    Nature; 1979 Jan; 277(5692):135-7. PubMed ID: 83539
    [No Abstract]   [Full Text] [Related]  

  • 10. Enhanced releasability of prostaglandin E2 and leukotrienes B4 and C4 from leukocytes of patients with atopic eczema.
    Ruzicka T; Ring J
    Acta Derm Venereol; 1987; 67(6):469-75. PubMed ID: 2451370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgG anti-IgE from atopic dermatitis induces mediator release from basophils and mast cells.
    Marone G; Casolaro V; Paganelli R; Quinti I
    J Invest Dermatol; 1989 Aug; 93(2):246-52. PubMed ID: 2787823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basophil mediator release in atopic dermatitis.
    Bull HA; Courtney PF; Bunker CB; Rustin MH; Pearce FL; Dowd PM
    J Invest Dermatol; 1993 Mar; 100(3):305-9. PubMed ID: 7680056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between antigen induced histamine release and cyclic AMP level in human leukocytes.
    Andersson RG; Colldahl H
    Acta Allergol; 1974 Aug; 29(4):248-55. PubMed ID: 4137913
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunopharmacology of the atopic diseases.
    Hanifin JM; Butler JM; Chan SC
    J Invest Dermatol; 1985 Jul; 85(1 Suppl):161s-164s. PubMed ID: 2409183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultraviolet A inhibits histamine release from human peripheral leukocytes.
    Ring J; Przybilla B; Eberlein B
    Int Arch Allergy Appl Immunol; 1989; 88(1-2):136-8. PubMed ID: 2468613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaphylactic reactions to suxamethonium prevention of mediator release by choline.
    Vervloet D; Arnaud A; Senft M; Didier A; Bongrand P; Charpin J
    J Allergy Clin Immunol; 1985 Aug; 76(2 Pt 1):222-5. PubMed ID: 2410473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro studies with fexofenadine, a new nonsedating histamine H1 receptor antagonist, on isolated human basophils.
    Amon U; Amon S; Gibbs BF
    Inflamm Res; 2000 Apr; 49 Suppl 1():S13-4. PubMed ID: 10864400
    [No Abstract]   [Full Text] [Related]  

  • 18. Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema.
    Ramírez del Pozo ME; Contreras Contreras E; López Tiro J; Gómez Vera J
    J Investig Allergol Clin Immunol; 2011; 21(5):416-7. PubMed ID: 21905512
    [No Abstract]   [Full Text] [Related]  

  • 19. [Use of anti-allergic immunoglobulin in children with allergic diseases].
    Balabolkin II; Stasiĭ ED; Dzhunelov AB; Abdyldaev TT; Imanalieva ChA; Guseva NV; Babaeva SB; Strigan VA
    Pediatriia; 1992; (1):76-8. PubMed ID: 1614810
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro releasability of histamine and serotonin: studies of atopic patients.
    Ring J; Allen DH; Mathison DA; Spiegelberg HL
    J Clin Lab Immunol; 1980 Mar; 3(2):85-91. PubMed ID: 6162959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.